Literature DB >> 32808453

Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer's clinical trials.

A Gleason1, S Ayton1, A I Bush1.   

Abstract

Entities:  

Keywords:  ARIA; Alzheimer’s disease; aducanumab; clinical trials; monoclonal antibodies

Mesh：

Substances：

Year:  2020        PMID： 32808453     DOI： 10.1111/ene.14484

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  4 in total

Review 1.  Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.

Authors:  Miguel Vaz; Vítor Silva; Cristina Monteiro; Samuel Silvestre
Journal:  Clin Interv Aging       Date:  2022-05-18       Impact factor: 3.829

Review 2.  Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.

Authors:  Semira Abdi Beshir; A M Aadithsoorya; Affana Parveen; Sheron Sir Loon Goh; Nadia Hussain; Vineetha Bharathan Menon
Journal:  Int J Alzheimers Dis       Date:  2022-03-09

3.  Amyloid PET ordering practices in a memory disorders clinic.

Authors:  Katherine W Turk; Ana Vives-Rodriguez; Kylie A Schiloski; Anna Marin; Ryan Wang; Prabhjyot Singh; Gabor P Hajos; Rachel Powsner; Renée DeCaro; Andrew E Budson
Journal:  Alzheimers Dement (N Y)       Date:  2022-08-17

Review 4.  The essential elements of Alzheimer's disease.

Authors:  Peng Lei; Scott Ayton; Ashley I Bush
Journal:  J Biol Chem       Date:  2020-11-27       Impact factor: 5.157
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.